Understanding Lennox-Gastuat Syndrome on LGS Awareness Day: Melanie Huntley, PhD
November 4th 2024The data scientist at Roche and mother of a child living with Lennox-Gastaut syndrome, provided insight on areas of the disease that need greater recognition, as well as an overview of how the disease is currently treated. [WATCH TIME: 4 minutes]
Radiprodil in TSC and FCD: Targeting Seizures through NMDA Modulation
November 4th 2024Bruce Leuchter, MD, president and chief executive officer at Neurvati Neurosciences, provided clinical insight on the newly initiated Astroscape trial of radiprodil for the treatment of tuberous sclerosis complex and focal cortical dysplasia type II.
The High Cost of Innovation: Navigating Rising Drug Prices in Neurology
November 3rd 2024Amy Tsou, MD, MSc, program director at the National Institutes of Neurological Disorders and Stroke, discussed the increasing cost of prescription drugs in the US and its impact on healthcare providers, including those who treat patients with neurologic conditions.
Alzheimer Agitation Therapy Brexpiprazole Maintains Safe Profile in Longitudinal Analysis
November 2nd 2024Over a 24-week period, comprising both the core study and extension trial, the incidence of treatment-emergent adverse events was infrequent, with less occurring over the long-term extension.
Lennox-Gastaut Syndrome: Unseen Challenges and the Need for Greater Awareness
November 1st 2024Ahead of International LGS Awareness Day, Melanie Huntley, PhD, a data scientist for Roche and mother of child with Lennox-Gastaut syndrome, shed light on the realities of living with LGS, emphasizing the need for greater awareness of the condition’s impact.
Eisai Formally Submits BLA for Subcutaneous Autoinjector of Lecanemab
November 1st 2024A subgroup analysis of the phase 3 Clarity AD open-label extension study showed a 14% increased amyloid plaque removal with subcutaneous lecanemab vs intravenous administration, the administration for which it was FDA-approved for.
Acumen Pharmaceuticals’ Phase 2 Advancements in Alzheimer Disease Screening: Todd Feaster, PsyD
November 1st 2024The senior clinical research scientist at Acumen Pharmaceuticals talked about the company's approach to refining Alzheimer screening by implementing plasma p-tau 217 biomarkers. [WATCH TIME: 5 minutes]
Using Biomarker Testing to Advance Alzheimer Diagnostics: Margherita Carboni, PhD
October 31st 2024The indication lead of neurology at Roche Diagnostics International talked about the latest Alzheimer biomarkers that are aimed to transform diagnostic accuracy and accessibility as well as enhance early detection and treatment. [WATCH TIME: 5 minutes]
Advancing Alzheimer Treatment Through Gamma Oscillation Stimulation: Ralph Kern, MD, MHSc
October 30th 2024The chief medical officer at Cognito Therapeutics talked about a medical device designed to slow cognitive decline in patients with Alzheimer disease through gamma frequency brain stimulation. [WATCH TIME: 6 minutes]